卡介苗细胞壁骨架用于胃癌术后辅助免疫治疗。一项随机临床试验的3至6年随访
Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial.
作者信息
Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y
出版信息
Cancer Immunol Immunother. 1983;14(3):167-71. doi: 10.1007/BF00205355.
The clinical effectiveness of immunotherapy with the cell wall skeleton of Bacillus Calmette-Guérin was assessed in a study involving 140 consecutive patients with gastric cancer, who were gastrectomized at a single institution from January 1976 through December 1978. These patients were randomized by an envelope method after operation and divided into three treatment groups: 'control', 'chemotherapy', and 'chemotherapy plus immunotherapy with BCG-CWS.' Only two patients who died during surgery were excluded, and a survey of survival periods was made on the remaining 138 patients in January 1982. As a result, statistically significant differences in the survival rate curve were observed between the control and chemotherapy plus immunotherapy groups (P less than 0.01), and between the chemotherapy and chemotherapy plus immunotherapy groups (P less than 0.05). These results emphasize effectiveness of BCG-CWS as an adjuvant immunotherapeutic agent in gastrectomized cancer patients.
在一项研究中评估了卡介苗细胞壁骨架免疫疗法的临床疗效，该研究纳入了1976年1月至1978年12月期间在单一机构接受胃切除术的140例连续胃癌患者。这些患者术后通过信封法随机分组，分为三个治疗组：“对照组”、“化疗组”和“化疗加卡介苗细胞壁骨架免疫治疗组”。仅排除了两名在手术期间死亡的患者，并于1982年1月对其余138例患者的生存期进行了调查。结果显示，对照组与化疗加免疫治疗组之间（P<0.01）以及化疗组与化疗加免疫治疗组之间（P<0.05）的生存率曲线存在统计学显著差异。这些结果强调了卡介苗细胞壁骨架作为胃切除术后癌症患者辅助免疫治疗剂的有效性。
Zotero 插件